Results from the Phase III RESPONSE Trial of Ruxolitinib versus Best Available Therapy for Patients with Polycythemia Vera


Results from the Phase III RESPONSE Trial of Ruxolitinib versus Best Available Therapy for Patients with Polycythemia Vera
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Mesa R et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or best available therapy: RESPONSE trial results. Proc ASH 2014;Abstract 709.

Vannucchi AM et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35. Abstract

Kiladjian J-J et al. Clinical benefit of ruxolitinib treatment after crossover from best available therapy in patients with polycythemia vera: Analysis of the RESPONSE trial. Proc ASH 2014;Abstract 3181.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.